Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Véronique Joly und 11 weiteren Autor:innen. Beteiligte Einrichtung: IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude …. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Adenine, HIV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
This retrospective study evaluated Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in 24 persons with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load <40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of BIC/FTC/TAF to treat HIV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP Laboratoire de Virologie, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Pharmacologie-Toxicologie, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
ORCID-Profile: Véronique Joly, Quentin Le Hingrat, Yazdan Yazdanpanah, Jade Ghosn
Zitieren
APA
Joly, V., Ferré, V. M., Le Hingrat, Q., Peytavin, G., Cresta, M., Charpentier, C., Digumber, M., Damond, F., Yazdanpanah, Y., Matheron, S., Descamps, D., & Ghosn, J. (2025). Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae447
Vancouver
Joly V, Ferré VM, Le Hingrat Q, Peytavin G, Cresta M, Charpentier C, et al. Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae447
BibTeX
@article{Joly2025,
author = {Joly, Véronique and Ferré, Valentine M and Le Hingrat, Quentin and Peytavin, Gilles and Cresta, Mélanie and Charpentier, Charlotte and Digumber, Marc and Damond, Florence and Yazdanpanah, Yazdan and Matheron, Sophie and Descamps, Diane and Ghosn, Jade},
title = {Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae447}
}
EUVIMED